{
    "clinical_study": {
        "@rank": "62158", 
        "arm_group": {
            "arm_group_label": "MM-398 + cyclophosphamide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The\n      goal is to find the highest dose of MM-398 that can be given safely when it is used together\n      with the chemotherapy drug Cyclophosphamide."
        }, 
        "brief_title": "Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors", 
        "condition": [
            "Recurrent or Refractory Solid Tumors", 
            "Ewing Sarcoma", 
            "Rhabdomyosarcoma", 
            "Neuroblastoma", 
            "Osteosarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neuroblastoma", 
                "Osteosarcoma", 
                "Rhabdomyosarcoma", 
                "Neoplasms", 
                "Sarcoma, Ewing's", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically-confirmed Ewing sarcoma, rhabdomyosarcoma,\n             neuroblastoma, or osteosarcoma\n\n          -  Disease progression after prior therapy in locally advanced or metastatic setting\n\n          -  Measurable or evaluable disease based on the Response Evaluation Criteria in Solid\n             Tumors (RECIST v1.1) criteria\n\n          -  Age 12 months to <21 years\n\n          -  Adequate bone marrow reserves, hepatic function, and renal function\n\n          -  Recovered from effects of any prior surgery or cancer therapy\n\n          -  Patients 18 years or older will provide written consent. A parent or legal guardian\n             of a patient <18 years of age will provide informed consent and patients 11 to 18\n             years of age will provide written assent or as per participating institutional\n             policy.\n\n        Exclusion Criteria:\n\n          -  Clinically significant gastrointestinal disorders\n\n          -  NYHA Class III or IV congestive heart failure, ventricular arrhythmias or\n             uncontrolled blood pressure\n\n          -  Active infection or unexplained fever\n\n          -  Known hypersensitivity to any of the components of MM-398 or other liposomal products\n\n          -  Recent Investigational therapy\n\n          -  Pregnant or breast feeding; females of child-bearing potential must test negative for\n             pregnancy at the time of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013336", 
            "org_study_id": "SPOC-2012-001"
        }, 
        "intervention": {
            "arm_group_label": "MM-398 + cyclophosphamide", 
            "intervention_name": "MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pediatric", 
            "MM-398", 
            "cyclophosphamide", 
            "irinotecan"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft Worth", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lubbock", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors", 
        "overall_contact": {
            "email": "amanda.knight@ttuhsc.edu", 
            "last_name": "Amanda Knight, RN, BSN, CCRP", 
            "phone": "806-743-2507", 
            "phone_ext": "307"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To determine the Maximum Tolerated Dose (MTD) of MM-398 in combination with intravenous cyclophosphamide by assessing the occurrence of dose limiting toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Measurement of plasma levels of study drug to determine the pharmacokinetic properties of MM-398 in combination with cyclophosphamide", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Merrimack Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "South Plains Oncology Consortium (SPOC)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Merrimack Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}